Brief: Ligand Pharmaceuticals Issues 2023 Financial Guidance

Ligand Pharmaceuticals Incorporated

13/12/2022 13:52

Dec 13 (Reuters) - Ligand Pharmaceuticals Inc  LGND.O :
    * LIGAND PHARMACEUTICALS INC - SEES 2023 TOTAL CORE REVENUE
OF
$118 MILLION TO $122 MILLION
    * LIGAND PHARMACEUTICALS INC - SEES ADJUSTED DILUTED EPS OF
$3.10
TO $3.30 IN 2023
    * LIGAND PHARMACEUTICALS INC - LIGAND ESTIMATES THAT AT END
OF
2022 IT WILL HAVE $150 MILLION OF CASH AND INVESTMENTS AVAILABLE
TO FUND ITS M&A INITIATIVES
    * LIGAND PHARMACEUTICALS INC - SEES 2023 TOTAL CASH
OPERATING
EXPENSES OF $46 MILLION

Source text for Eikon:  ID:nBw3GQvFTa 
Further company coverage:  LGND.O 
 ((Reuters.Briefs@thomsonreuters.com;))